Should I buy or sell BriaCell Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BriaCell Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BCT shares. View BCT analyst ratings or view top-rated stocks .

How have BCT shares performed in 2024?

BriaCell Therapeutics' stock was trading at C$7.80 at the beginning of the year. Since then, BCT stock has decreased by 76.0% and is now trading at C$1.87. View the best growth stocks for 2024 here .

When is BriaCell Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 12th 2024. View our BCT earnings forecast .

How were BriaCell Therapeutics' earnings last quarter?

BriaCell Therapeutics Corp. (TSE:BCT) issued its quarterly earnings data on Monday, March, 18th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.68.

How do I buy shares of BriaCell Therapeutics?

Shares of BCT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor , Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. Compare Top Brokerages Here .

TSE:BCT

BriaCell Therapeutics (BCT) Stock Price, News & Analysis

→ Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad)

Free BCT Stock Alerts

C$1.87

-0.09 (-4.59%)

(As of 05/17/2024 ET)

Compare

Today's Range: C$1.80
▼
C$2.05
50-Day Range: C$1.87
▼
C$4.05
52-Week Range: C$1.80
▼
C$10.29

Volume: 10,940 shs
Average Volume: 8,220 shs
Market Capitalization: C$29.88 million

P/E Ratio: N/A
Dividend Yield: 13.70%
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Competitors Earnings

Get BriaCell Therapeutics alerts:

Ad Crypto 101 Media

[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks

Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls.

Claim your free seat by clicking here now.

About BriaCell Therapeutics

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

BCT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BCT Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive BCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/18/2024
Today: 5/18/2024
Next Earnings (Estimated): 6/12/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: TSE
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: TSE:BCT
CUSIP: N/A
CIK: N/A
Web: www.briacell.com
Phone: 604-921-1810
Fax: N/A
Employees: 16
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): C($1.08)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: C$-12,610,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -206.01%
Return on Assets: -85.45%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.99
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: C($0.50) per share
Price / Book: -3.74

Miscellaneous

Outstanding Shares: 15,980,000
Free Float: N/A
Market Cap: C$29.88 million
Optionable: Not Optionable
Beta: 1.75

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. William V. Williams M.D. (Age 69)
CEO, President & Director
Comp: $1.08M
Mr. Gadi Levin B.Com. (Age 51)
C.A., CPA, M.B.A., CFO & Corporate Secretary
Comp: $419.25k
Dr. Miguel A. Lopez-Lago Ph.D. (Age 55)
Chief Scientific Officer
Comp: $411.58k
Dr. Giuseppe Del Priore M.D. (Age 62)
M.P.H., MPH, Chief Medical Officer
Comp: $678.18k
Dr. Charles Louis Wiseman FACP (Age 78)
M.D., Founder, Principal Research Advisor & Member of Scientific Advisory Board
Comp: $332.05k

Key Competitors

View All Competitors

BCT Stock Analysis - Frequently Asked Questions

Should I buy or sell BriaCell Therapeutics stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BriaCell Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BCT shares.
View BCT analyst ratings or view top-rated stocks.
How have BCT shares performed in 2024?: BriaCell Therapeutics' stock was trading at C$7.80 at the beginning of the year. Since then, BCT stock has decreased by 76.0% and is now trading at C$1.87.
View the best growth stocks for 2024 here.
When is BriaCell Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 12th 2024.
View our BCT earnings forecast.

How were BriaCell Therapeutics' earnings last quarter?: BriaCell Therapeutics Corp. (TSE:BCT) issued its quarterly earnings data on Monday, March, 18th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.68.
How do I buy shares of BriaCell Therapeutics?: Shares of BCT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:BCT) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial